MIST Milestone Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1408443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-68.7%
TTM EPS YoY6.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,370.6%
ROA-78.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets103.8%
Debt / equity—
Current ratio6.27x
Interest coverage-7.62x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $18.11M | $14.36M |
| SG&A expense | $17.27M | $16.74M |
| Operating income | -$62.14M | -$42.10M |
| Interest expense | $3.84M | $3.58M |
| Pretax income | -$63.06M | -$41.52M |
| Net income | -$63.06M | -$41.52M |
| EBITDA | -$62.03M | -$42.00M |
| EPS (basic) | -0.75 | -0.67 |
| EPS (diluted) | -0.75 | -0.67 |
| Balance sheet | ||
| Cash & equivalents | $73.05M | $25.31M |
| Short-term investments | $32.91M | $44.38M |
| Inventory | $648,000 | — |
| Current assets | $111.92M | $73.93M |
| PP&E, net | $511,000 | $197,000 |
| Total assets | $113.56M | $75.50M |
| Current liabilities | $13.98M | $8.13M |
| Long-term debt | $57.19M | $53.35M |
| Total debt | $57.19M | $53.35M |
| Total liabilities | $71.79M | $62.35M |
| Shareholders' equity | $41.77M | $13.15M |
| Net debt | -$15.86M | $28.04M |
| Shares outstanding | 106.24M | 53.35M |
| Cash flow statement | ||
| Operating cash flow | -$49.04M | -$28.85M |
| Capital expenditure | $302,000 | $33,000 |
| Free cash flow | -$49.34M | -$28.88M |
| Investing cash flow | $11.25M | $8.28M |
| Financing cash flow | $85.53M | $32.12M |
| Depreciation & amortization | $114,000 | $105,000 |
| Stock-based compensation | $7.46M | $5.78M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.